USA • New York Stock Exchange • NYSE:PRGO • IE00BGH1M568
The current stock price of PRGO is 14.64 USD. In the past month the price decreased by -0.41%. In the past year, price decreased by -40.49%.
ChartMill assigns a technical rating of 1 / 10 to PRGO. When comparing the yearly performance of all stocks, PRGO is a bad performer in the overall market: 84.12% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to PRGO. While PRGO is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months PRGO reported a non-GAAP Earnings per Share(EPS) of 2.9. The EPS increased by 16.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.51% | ||
| ROE | -1.16% | ||
| Debt/Equity | 0.81 |
10 analysts have analysed PRGO and the average price target is 19.04 USD. This implies a price increase of 30.05% is expected in the next year compared to the current price of 14.64.
For the next year, analysts expect an EPS growth of 10.45% and a revenue growth -4.31% for PRGO
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 965.082B | ||
| JNJ | JOHNSON & JOHNSON | 20.76 | 572.907B | ||
| MRK | MERCK & CO. INC. | 22.54 | 297.222B | ||
| PFE | PFIZER INC | 9.06 | 150.614B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 121.168B | ||
| ZTS | ZOETIS INC | 18.6 | 55.849B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.456B | ||
| VTRS | VIATRIS INC | 5.78 | 16.516B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.9 | 12.079B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.48 | 9.116B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Perrigo Co. Plc is a pure-play self-care company provider of consumer self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company is headquartered in Dublin, Dublin and currently employs 8,379 full-time employees. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. The company primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
PERRIGO CO PLC
The Sharp Building, Hogan Place, Dublin 2
DUBLIN DUBLIN 49010 IE
CEO: Murray S. Kessler
Employees: 8379
Phone: 35317094000
Perrigo Co. Plc is a pure-play self-care company provider of consumer self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company is headquartered in Dublin, Dublin and currently employs 8,379 full-time employees. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. The company primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
The current stock price of PRGO is 14.64 USD. The price increased by 2.59% in the last trading session.
PERRIGO CO PLC (PRGO) has a dividend yield of 8.13%. The yearly dividend amount is currently 1.12.
PRGO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRGO.
The Revenue of PERRIGO CO PLC (PRGO) is expected to decline by -4.31% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
PERRIGO CO PLC (PRGO) currently has 8379 employees.